Clinical Trials

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03765983 2026-01-22

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

17 enrolled

Breast Neoplasms

NCT04578106 2026-01-06

ELPIS

5 enrolled 7 charts

Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

13 enrolled

Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

2 enrolled 6 charts

Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

2 enrolled

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

17 enrolled 16 charts

Breast Neoplasms, Meningeal Neoplasms

NCT04789096 2025-06-06

TUGETHER

31 enrolled

Breast Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

96 enrolled 16 charts

Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast Neoplasms

NCT04675827 2024-12-04

Decrescendo

139 enrolled

Breast Neoplasms

NCT00963547 2024-06-04

MK-2206-015

33 enrolled 13 charts

Breast Neoplasms

NCT02771795 2024-02-02

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Terminated

538 enrolled 9 charts

Breast Neoplasms, Neoplasms

NCT01873833 2023-10-05

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

10 enrolled 16 charts

Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

63 enrolled 22 charts

Breast Neoplasms

NCT00004935 2023-04-18

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

175 enrolled

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

201 enrolled 71 charts

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

7 enrolled 8 charts

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

BreastGastrointestinalThoracic

2 enrolled 9 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT04102618 2022-08-15

AWARE-1

Phase EARLY_PHASE1 Terminated

26 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

2 enrolled 7 charts

Breast Neoplasms

NCT00810017 2022-05-19

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

2 enrolled 3 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

42 enrolled 13 charts

Breast Neoplasms

NCT02907918 2021-09-29

PALTAN

26 enrolled 8 charts

Breast Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

6 enrolled

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

66 enrolled 40 charts

Breast Neoplasms

NCT00138125 2020-10-19

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

2 enrolled 5 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

3,509 enrolled

Breast Neoplasms

NCT04066790 2020-05-19

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

12 enrolled

Breast Neoplasms

NCT02774681 2020-04-14

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

12 enrolled 11 charts

Breast Neoplasms

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

6 enrolled

BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

16 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02318901 2019-10-21

PembroMab

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02598310 2019-08-28

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

30 enrolled

Breast Neoplasms

NCT00130507 2019-02-26

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

14 enrolled

Breast Neoplasms

NCT01185509 2019-01-23

Trastuzumab and Vinorelbine in Advanced Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT01912963 2018-12-05

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

32 enrolled 15 charts

Breast Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

44 enrolled 6 charts

Breast Neoplasms

NCT01690325 2018-08-13

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

21 enrolled

Breast Neoplasms

NCT00169104 2018-07-20

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Phase 2/3 Terminated

23 enrolled 10 charts

Breast Neoplasms

NCT02598427 2018-02-28

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

1 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00864175 2018-01-18

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

68 enrolled

Breast Neoplasms

NCT01187381 2017-10-20

HERODOT

Terminated

250 enrolled 12 charts

Breast Neoplasms

NCT01512199 2017-10-18

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

29 enrolled